Discussant review: Impact of a single or two dose regimen of inclisiran, a novel siRNA inhibitor to PCSK9 on time averaged reductions in LDL-C over 1 year. ORION 1
Topic:
Lipids (Epidemiology and Prevention)
Speaker:
Professor P. Barter (Sydney, AU)
Event:
ESC Congress 2017
Congress Presentation
About the speaker
Professor Philip Barter
University of New South Wales Sydney, Sydney (Australia)
6
presentations
0
follower
17 more presentations in this session
Access the full session
Hot Line: Late-Breaking Clinical Trials 2
Speakers:
Professor P. Barter, Professor M. Boehm, Professor B. Williams, Professor M. Ezekowitz, Professor J. Nielsen
About the event
ESC 365 is supported by
